Tags : Solar-1

Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III

 Shots: The P-III SOLAR-1 trial assessed BYL719 (300 mg, qd) + fulvestrant (500 mg) vs PBO (fulvestrant) in 572 postmenopausal women in ratio (1:1) with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer P-III SOLAR-1 trial results: mPFS (11.0 vs 6.8 mos.), additional 1L therapy mPFS (10.9 vs 3.7 mos.), PIK3CA mutation (3% vs 2%), safe […]Read More